New drug targets for alcoholic liver disease

Hepatology International

Volumn 8, Issue 2, 2014, Pages 475-480

  Xu, Mingjiang ^a   Chang, Binxia ^a   Mathews, Stephanie ^a   Gao, Bin ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

Ethanol; Inflammation; Interleukin 22; Liver; Prednisolone

Indexed keywords

CELL ADHESION MOLECULE; CHEMOKINE; CHEMOKINE RECEPTOR; EMRICASAN; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 22; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OSTEOPONTIN; OXECLOSPORIN; PENTOXIFYLLINE; PLACEBO; PREDNISOLONE; PROBIOTIC AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; STEROID; TUMOR NECROSIS FACTOR; ZINC SULFATE;

ACUTE LIVER FAILURE; ACUTE ON CHRONIC LIVER FAILURE; ALCOHOL LIVER CIRRHOSIS; ALCOHOL LIVER DISEASE; ALCOHOLIC FATTY LIVER; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BACTERIAL INFECTION; COMPLEMENT ACTIVATION; HEPATITIS; HUMAN; INFLAMMATION; INTESTINE FLORA; LACTOBACILLUS RHAMNOSUS; LIVER FIBROSIS; LIVER NECROSIS; LIVER PROTECTION; LIVER REGENERATION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; SEPTIC SHOCK; SHORT TERM SURVIVAL; STEROID THERAPY; UNSPECIFIED SIDE EFFECT;

EID: 84919433876     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-014-9516-x     Document Type: Article

References (41)

1. Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 2011;141:1572–1585
2. Wang HJ, Gao B, Zakhari S, Nagy LE. Inflammation in alcoholic liver disease. Annu Rev Nutr 2012;32:343–368
3. Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med 2009;360:2758–2769
4. Mathurin P, O’Grady J, Carithers RL, Phillips M, Louvet A, Mendenhall CL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut 2011;60:255–260
5. Nguyen-Khac E, Thevenot T, Piquet MA, Benferhat S, Goria O, Chatelain D, et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med 2011;365:1781–1789
6. Singal AK, Shah VH. Alcoholic hepatitis: prognostic models and treatment. Gastroenterol Clin North Am 2011;40:611–639
7. Christensen E. Glucocorticosteroids in acute alcoholic hepatitis: the evidence of a beneficial effect is getting even weaker. J Hepatol 2010;53:390–391
8. Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw AJ, Pavord ID. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002;57:875–879
9. Cox G. Glucocorticoid treatment inhibits apoptosis in human neutrophils. Separation of survival and activation outcomes. J Immunol 1995;154:4719–4725
10. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987;317:653–658
11. Lin F, Taylor NJ, Su H, Huang X, Hussain MJ, Abeles RD, et al. Alcohol dehydrogenase-specific T-cell responses are associated with alcohol consumption in patients with alcohol-related cirrhosis. Hepatology 2013;58:314–324
12. Tanner AR, Powell LW. Corticosteroids in liver disease: possible mechanisms of action, pharmacology, and rational use. Gut 1979;20:1109–1124
13. Kwon HJ, Won YS, Park O, Feng D, Gao B. Opposing effects of prednisolone treatment on T/NKT cell- and hepatotoxin-mediated hepatitis in mice. Hepatology 2013;. doi:10.1002/hep.26748
14. Dominguez M, Miquel R, Colmenero J, Moreno M, Garcia-Pagan JC, Bosch J, et al. Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis. Gastroenterology 2009;136:1639–1650
15. Colmenero J, Bataller R, Sancho-Bru P, Bellot P, Miquel R, Moreno M, et al. Hepatic expression of candidate genes in patients with alcoholic hepatitis: correlation with disease severity. Gastroenterology 2007;132:687–697
16. Bertola A, Park O, Gao B. Chronic plus binge ethanol feeding synergistically induces neutrophil infiltration and liver injury: a critical role for E-selectin. Hepatology 2013;58:1814–1823
17. Adams DH, Hubscher SG, Fisher NC, Williams A, Robinson M. Expression of E-selectin and E-selectin ligands in human liver inflammation. Hepatology 1996;24:533–538
18. Mandrekar P, Ambade A, Lim A, Szabo G, Catalano D. An essential role for monocyte chemoattractant protein-1 in alcoholic liver injury: regulation of proinflammatory cytokines and hepatic steatosis in mice. Hepatology 2011;54:2185–2197
19. Urtasun R, Lopategi A, George J, Leung TM, Lu Y, Wang X, et al. Osteopontin, an oxidant stress sensitive cytokine, up-regulates collagen-I via integrin alpha(V)beta(3) engagement and PI3K/pAkt/NFkappaB signaling. Hepatology 2012;55:594–608
20. Pritchett J, Harvey E, Athwal V, Berry A, Rowe C, Oakley F, et al. Osteopontin is a novel downstream target of SOX9 with diagnostic implications for progression of liver fibrosis in humans. Hepatology 2012;56:1108–1116
21. Morales-Ibanez O, Dominguez M, Ki SH, Marcos M, Chaves JF, Nguyen-Khac E, et al. Human and experimental evidence supporting a role for osteopontin in alcoholic hepatitis. Hepatology 2013;58:1742–1756
22. Ge X, Leung TM, Arriazu E, Lu Y, Urtasun R, Christensen B, et al. Osteopontin binding to lipopolysaccharide lowers tumor necrosis factor-alpha and prevents early alcohol-induced liver injury in mice. Hepatology 2013;. doi:10.1002/hep.26931
23. Lazaro R, Ueno A, Do R, Zhu L, Wu R, Xu J, et al. Mouse model of alcoholic hepatitis: no role of osteopontin. Hepatology 2013;58:834A
24. Hartmann P, Chen WC, Schnabl B. The intestinal microbiome and the leaky gut as therapeutic targets in alcoholic liver disease. Front Physiol 2012;3:402
25. Hartmann P, Chen P, Wang HJ, Wang L, McCole DF, Brandl K, et al. Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice. Hepatology 2013;58:108–119
26. Yan AW, Fouts DE, Brandl J, Starkel P, Torralba M, Schott E, et al. Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology 2011;53:96–105
27. Pritchard MT, McMullen MR, Medof ME, Stavitsky A, Nagy LE. Role of complement in ethanol-induced liver injury. Adv Exp Med Biol 2008;632:175–186
28. Mathews S, Gao B. Therapeutic potential of interleukin 1 inhibitors in the treatment of alcoholic liver disease. Hepatology 2013;57:2078–2080
29. Petrasek J, Bala S, Csak T, Lippai D, Kodys K, Menashy V, et al. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J Clin Invest 2012;122:3476–3489
30. Jung Y, Brown KD, Witek RP, Omenetti A, Yang L, Vandongen M, et al. Accumulation of hedgehog-responsive progenitors parallels alcoholic liver disease severity in mice and humans. Gastroenterology 2008;134:1532–1543
31. Sancho-Bru P, Altamirano J, Rodrigo-Torres D, Coll M, Millan C, Jose Lozano J, et al. Liver progenitor cell markers correlate with liver damage and predict short-term mortality in patients with alcoholic hepatitis. Hepatology 2012;55:1931–1941
32. Gao B. Hepatoprotective and anti-inflammatory cytokines in alcoholic liver disease. J Gastroenterol Hepatol 2012;27(Suppl 2):89–93
33. Kong X, Feng D, Wang H, Hong F, Bertola A, Wang FS, et al. Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice. Hepatology 2012;56:1150–1159
34. Meng F, Wang K, Aoyama T, Grivennikov SI, Paik Y, Scholten D, et al. Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology 2012;143:765–776
35. Radaeva S, Sun R, Pan HN, Hong F, Gao B. Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology 2004;39:1332–1342
36. Ki SH, Park O, Zheng M, Morales-Ibanez O, Kolls JK, Bataller R. Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: role of signal transducer and activator of transcription 3. Hepatology 2010;52:1291–1300
37. Rubino SJ, Geddes K, Girardin SE. Innate IL-17 and IL-22 responses to enteric bacterial pathogens. Trends Immunol 2012;33:112–118
38. Xu M, Feng D, Wang H, Guan Y, Yan X, Gao B. Interleukin-22 ameliorates renal ischemia-reperfusion injury via the activation of STAT3 and AKT in the renal proximal tubule epithelial cells. J Am Soc Nephrol 2013; in press
39. Park O, Wang H, Weng H, Feigenbaum L, Li H, Yin S, et al. In vivo consequences of liver-specific interleukin-22 expression in mice: implications for human liver disease progression. Hepatology 2011;54:252–261
40. Feldstein AE, Gores GJ. Apoptosis in alcoholic and nonalcoholic steatohepatitis. Front Biosci 2005;10:3093–3099
41. Roychowdhury S, McMullen MR, Pisano SG, Liu X, Nagy LE. Absence of receptor interacting protein kinase 3 prevents ethanol-induced liver injury. Hepatology 2013;57:1773–1783